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A heparin cofactor II (HCII) mutant with an Arg sub-
stituted for Leu444 at the P1 position (L444R-rHCII) was
previously found to have altered proteinase specificity
(Derechin, V. M., Blinder, M. A., and Tollefsen, D. M.
(1990) J. Biol. Chem. 265, 5623–5628). The present study
characterizes the effect of glycosaminoglycans on the
substrate versus inhibitor activity of L444R-rHCII. Hep-
arin increased the stoichiometry of inhibition of L444R-
rHCII with a-thrombin (compared with minus glyco-
saminoglycan) but decreased it with R93A,R97A,R101A-
thrombin, a mutant thrombin that does not bind
glycosaminoglycans. Dermatan sulfate decreased the
stoichiometry of inhibition of L444R-rHCII with both
proteinases. SDS-polyacrylamide gel electrophoresis
showed no proteolysis of L444R-rHCII when incubated
with R93A,R97A,R101A-thrombin in the absence or the
presence of glycosaminoglycan or with a-thrombin and
dermatan sulfate. In contrast, greater than 75% of the
L444R-rHCII was converted to a lower molecular weight
form when incubated with a-thrombin/heparin. A time
course of a-thrombin inhibition by L444R-rHCII/hepa-
rin showed a rapid but transient inhibition with approx-
imately 80% of the a-thrombin activity being regained
after 6 h of incubation. In contrast, all other combina-
tions of inhibitor, proteinase, and glycosaminoglycan
resulted in complete and sustained inhibition of the pro-
teinase. Heparin fragments of 8–20 polysaccharides in
length rapidly accelerated L444R-rHCII inhibition of
both a-thrombin and R93A,R97A,R101A-thrombin. After
extended incubations, R93A,R97A,R101A-thrombin was
completely inhibited by L444R-rHCII with all the hepa-
rin fragments, but approximately 30–50% of a-thrombin
activity remained with fragments long enough to bridge
HCII-thrombin. These results collectively indicate that
ternary complex formation, mediated by heparin, in-
creases L444R-rHCII inactivation by a-thrombin.
Serine proteinase inhibitors (serpins)1 are a highly con-
served family of proteins whose primary role is to regulate the
activity of a wide variety of serine proteinases involved in
processes such as blood coagulation, fibrinolysis, inflammation,
and cancer metastasis (1–3). Serpins inhibit their target pro-
teinase by functioning as suicide substrates. The serpin con-
tains a peptide bond, termed P1-P19 by the nomenclature of
Schechter and Berger (4), within an exposed region, called the
reactive site loop, that is recognized as a substrate by the
proteinase (2). The initial binding of the serpin and proteinase
results in the formation of a Michaelis complex, which can then
partition between a kinetically stable intermediate, resulting
in proteinase inhibition, and a cleaved inactive inhibitor (3, 5,
6). Although the sequence of the amino acids in the reactive site
loop and on the P1-P19 residues in particular determines in
part the proteinase specificity of the serpin, they also deter-
mine the partitioning of the serpin into an inhibitor versus
substrate pathway with a given proteinase.
Heparin cofactor II (HCII), protein C inhibitor, protease
nexin-1, plasminogen activator inhibitor-1, and antithrombin
III (AT) belong to a subgroup of serpins whose inhibitory ac-
tivity is accelerated upon binding to glycosaminoglycans, such
as heparin, heparan sulfate, and dermatan sulfate (Refs. 1–3
and 7–9) and references therein). AT has a P1-P19 Arg-Ser
reactive site, and this serpin is important for regulating hemo-
stasis because it inhibits thrombin and most other coagulation
proteinases in the presence of heparin or heparan sulfate.
Glycosaminoglycan-accelerated thrombin inhibition by AT re-
quires the formation of a ternary complex in which heparin
binds AT and thrombin simultaneously (10). Thrombin inhibi-
tion by AT in the presence of heparin is accelerated more than
1,000-fold. In contrast to AT, the target proteinase of HCII is
believed to be only thrombin (11, 12), a pluripotent serine
proteinase with additional biological roles in inflammation and
wound healing. The P1-P19 bond of HCII (Leu444–Ser445) is an
unusual thrombin substrate sequence because all coagulation
proteinases prefer Arg at the P1 position (13, 14). Thus, in the
absence of glycosaminoglycan, HCII is a poor thrombin inhib-
itor. However, HCII is a exceptional thrombin inhibitor in the
presence of heparin or dermatan sulfate, either of which can
accelerate the thrombin inhibition rate more than 9,000-fold (7,
15–17). Although heparin can simultaneously bind thrombin
and HCII, ternary complex formation does not appear to be
absolutely required for thrombin inhibition by HCII (18).
Mutations in the reactive site loop of AT (19), a1-antichymot-
rypsin (20, 21), and protein C inhibitor (22) have been shown to
affect the inhibitor versus substrate properties of the serpin. In
addition, exogenous factors such as heparin and ionic strength
(23) and the addition of peptides that insert into the b-sheet of
a serpin (24) can also change the serpin from an inhibitor to a
substrate. An HCII mutant with an Arg substituted for Leu444
at the P1 position (L444R-rHCII) was previously engineered
and characterized by Derechin et al. (25). Consistent with
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thrombin preferring a P1 Arg residue, the thrombin inhibition
rate of the mutant in the absence of glycosaminoglycan was
about 100-fold higher than wild type recombinant HCII (wt-
rHCII). Because a P1 Leu to Arg mutation in HCII caused
increased thrombin inhibitory activity in the absence of glyco-
saminoglycans (25), we became interested in determining
whether this mutation altered HCII’s inhibitor versus sub-
strate properties in the absence or the presence of glycosami-
noglycans. In this report we demonstrate that (a) although
L444R-rHCII is a better thrombin inhibitor, it is also a better
thrombin substrate, (b) heparin promotes L444R-rHCII inacti-
vation by a-thrombin in a mechanism dependent upon ternary
complex formation, (c) dermatan sulfate does not promote
L444R-rHCII inactivation, and (d) the effect of heparin on
inactivation is manifested only with L444R-rHCII and not with
wt-rHCII.
EXPERIMENTAL PROCEDURES
Generation and Expression of wt-rHCII and L444R-rHCII—Human
wild type recombinant HCII (cDNA kindly provided by Dr. Douglas M.
Tollefsen, Washington University School of Medicine, St. Louis, MO)
was previously expressed in the baculovirus expression system and
characterized (17). To obtain L444R-rHCII, site-directed mutagenesis
was performed by the method of Kunkel (26) on a XhoI-EcoRI HCII
cDNA cassette subcloned in the pBluescript SK1 mutagenesis and
cloning vector (Stratagene). Positive clones were identified by DNA
sequencing (Sequenase®, version 2.0, U. S. Biochemical). A XhoI-EcoRI
cassette containing the mutation was subcloned into full-length HCII
cDNA in the pGEM®-3 blue vector (Promega). Full-length HCII cDNA
was then subcloned into the baculoviral transfer vector pVL1392
(PharMingen) via flanking EcoRI sites and co-transfected with linear-
ized Autographica californica nuclear polyhedrosis virus (AcNPV) into
Spodoptera frugiperda (Sf9, InVitrogen) insect cells (27). The infectious
medium was collected 4 days post-transfection and used in plaque
assays as described in PharMingen protocols. Individual plaques were
isolated and amplified by infection of Sf9 cells in 24-well plates. Pro-
duction of rHCII was determined by immunoblot analysis of whole cell
lysates from plaque-infected cells; positive clones were amplified and
stored at 4 °C. Sf9 cells were maintained in spinner flasks in Grace’s
medium (JRH Scientific) supplemented with 10% fetal bovine serum
(HiClone), 0.3 g/liter L-glutamine (Life Technologies, Inc.), and 50 mg/ml
gentamicin (Life Technologies, Inc.).
Protein Expression and Purification—High Fivey insect cells (In-
Vitrogen) grown at 27 °C in serum free Ex-Cell 405 medium with
L-glutamine (JRH Scientific) were used to express rHCII. Typically, two
T150 flasks of High Fivey cells were infected with viral stock (200
ml/flask). The cell supernatant was collected after 2 days and centri-
fuged at 350 3 g for 5 min to remove cell debris. The medium was
diluted with an equal volume of HPN buffer, pH 6.5 (20 mMHepes, 0.1%
polyethylene glycol 8000, 0.05% NaN3), and batch adsorbed with 0.5 ml
of heparin-Sepharose beads (Pharmacia Biotech Inc.) for 1 h at 4 °C.
rHCII was eluted from the heparin-Sepharose with 0.5 M NaCl in HPN
buffer, pH 7.4, after two washes in 75 mM NaCl in HPN, pH 6.5. The
heparin-Sepharose eluate was diluted in HPN buffer to a final concen-
tration of 50 mM NaCl, pH 7.8, and batch adsorbed with 0.5 ml of
Q-Sepharose (Sigma) for 1 h at 4 °C. After two washes in 50 mM NaCl,
the protein was eluted with 0.5 M NaCl in HPN buffer, pH 7.8. The
eluate was stored at 280 °C.
rHCII Immunodetection—A direct enzyme-linked immunosorbent
assay using a mouse anti-HCII monoclonal antibody and a goat anti-
mouse IgG conjugated to alkaline phosphatase (Sigma) was used as
described previously to measure rHCII concentrations (17). Human
plasma HCII, purified as described previously (28) was used as a
standard. Assays were performed in 96-well microtiter plates and color
development was monitored at 405 nm on a Vmax microplate reader
(Molecular Devices). For immunoblot analysis, rHCII was subjected to
SDS-polyacrylamide gel electrophoresis (PAGE) (29) and electro-
phoretically transferred to a polyvinylidene difluoride membrane (Im-
mobilon-P, Millipore). The membrane was probed with the anti-HCII
monoclonal antibody, followed by goat anti-mouse IgG conjugated to
horseradish peroxidase (Sigma) as described previously (17). Im-
munoreactive bands were detected by enhanced chemiluminescence
(Amersham Corp.).
Inhibition Rate Constants—Human a-thrombin was prepared from
blood plasma prothrombin as detailed previously (30). Wild type recom-
binant thrombin and R93A,R97A,R101A-thrombin were kindly pro-
vided by Dr. Charles T. Esmon (31). R93A,R97A,R101A-thrombin is a
recombinant thrombin that contains three point mutations in anion-
binding exosite 2, the putative glycosaminoglycan-binding site, that
results in significantly reduced heparin affinity (31). Compared with
wild type recombinant thrombin, R93A,R97A,R101A-thrombin inhibi-
tion in the presence of heparin or dermatan sulfate with HCII was not
dramatically changed (Table I).2 Chromogenic substrate was tosyl-Gly-
Pro-Arg-p-nitroanilide (Boehringer Mannheim). Heparin (Diosynth,
The Netherlands) and dermatan sulfate (Calbiochem; nitrous acid-
treated to remove contaminating heparin and heparan sulfate) were
used for the glycosaminoglycan-accelerated thrombin inhibition assays.
All assays were performed at room temperature in 96-well microtiter
plates (previously coated with 2 mg/ml bovine serum albumin), and
color development was monitored at 405 nm on a Vmax microplate
reader. Second order inhibition rates (k2, M
21 min21) were obtained as
follows. In the absence of glycosaminoglycan, 200 nM wt-rHCII or 25 nM
L444R-rHCII were incubated with 1 nM thrombin in the presence of 50
mg/ml polybrene (Sigma) and 2 mg/ml bovine serum albumin in HNPN,
pH 7.4 (20 mM Hepes, 150 mM NaCl, 0.1% polyethylene glycol 8000,
0.05% NaN3) for a range of time periods. For glycosaminoglycan-accel-
erated thrombin inhibition, 5 nM HCII, and 0.5 nM thrombin were
incubated with increasing amounts of heparin or dermatan sulfate for
20–60 s. Inhibition was quenched with 150 mM tosyl-Gly-Pro-Arg-p-
nitroanilide and 3 mg/ml polybrene. Second order inhibition rate con-
stants were measured in triplicate on two to three different prepara-
tions of rHCII. The rates were obtained under pseudo-first order
reaction conditions ([I] ... [E]) and were calculated using the equa-
tion k2 5 (2ln a)/t[I], where a is the residual proteinase activity, t is the
association time, and [I] is the HCII concentration (32).
Stoichiometry of Inhibition Assays—Experiments were performed in
triplicate in 96-well bovine serum albumin-coated microtiter plates at
room temperature in a reaction buffer containing 2 mg/ml bovine serum
albumin in HNPN, pH 7.4. Stoichiometry of inhibition (SI) was deter-
mined by incubating increasing amounts of rHCII with 1 nM thrombin
for 100 min in the absence or the presence of 5 mg/ml heparin or 20
mg/ml dermatan sulfate. This incubation time was greater than three
half-lives of inhibition of the lowest inhibition rate (20, 22). The reaction
was quenched with tosyl-Gly-Pro-Arg-p-nitroanilide and polybrene, and
the residual thrombin activity was measured as described above. SI
values were calculated by extrapolating the initial slope of a plot of
thrombin activity on the y axis versus the ratio of rHCII/thrombin
concentration on the x axis.
Visualization of rHCII-Thrombin Complexes and rHCII Proteolysis
Products—HCII (100 nM) was incubated with thrombin (10 nM) in
HNPN, pH 7.4, in the absence of glycosaminoglycan or in the presence
of either 5 mg/ml heparin or 20 mg/ml dermatan sulfate for 1, 5, and 30
min at room temperature. The reaction was terminated by the addition
of 5 mM D-Phe-Pro-Arg-chloromethyl ketone (Calbiochem), which inac-
tivates uncomplexed thrombin, and Laemmli sample buffer. SDS-
PAGE and immunoblotting with an anti-HCII monoclonal antibody
were performed as described above.
Extended Time Course Studies—HCII (10 nM) and thrombin (1 nM)
were incubated in HNPN, pH 7.4 in the absence of glycosaminoglycan
or in the presence of 5 mg/ml heparin or 20 mg/ml dermatan sulfate for
various time points up to 18 h, and the residual thrombin activity was
measured as described above. To determine the affect of ternary com-
plex formation on substrate versus inhibitor properties of HCII, 1 nM
thrombin and 10 nM HCII were incubated for 18 h in the presence of
heparin fragments (1.4 mM, 3.4–8.4 mg/ml; Stago Diagnostica, kindly
provided by Dr. Michel M. Canton) ranging from 8 to 20 oligosaccha-
rides in length (HF8, HF12, HF16, and HF20). A low evaporation lid
coated with anti-fogging agent (Molecular Devices) was used to mini-
mize evaporation.
RESULTS
Generation, Expression, and Kinetic Analysis of L444R-rH-
CII—L444R-rHCII was generated, expressed, and purified as
described under “Experimental Procedures.” In a typical prep-
aration, 50–130 mg of protein were obtained from two T150
flasks of High Five cells after sequential heparin- and Q-Sepha-
rose batch adsorption of the conditioned medium. Immunoblot
analysis and SDS-PAGE showed that L444R-rHCII co-mi-
2 S. T. Cooper, A. R. Rezaie, C. T. Esmon, and F. C. Church, unpub-
lished results.
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grated with wt-rHCII as a single band of approximately 70
kDa.
The data comparing the inhibition rate constants of L444R-
rHCII and wt-rHCII with a-thrombin in the absence and the
presence of glycosaminoglycan are summarized in Table I. As
shown previously by Derechin et al. (25), replacement of the P1
leucine of HCII with an arginine greatly increases the throm-
bin inhibition rate in the absence of glycosaminoglycan. Com-
pared with wt-rHCII, L444R-rHCII had a 54-fold higher rate of
inhibition of a-thrombin. However, in the presence of optimal
concentrations of either heparin or dermatan sulfate, the max-
imal inhibition rate of L444R-rHCII was approximately 5-fold
lower than for wt-rHCII.
Wild type rHCII and L444R-rHCII were then tested for their
ability to inhibit wild type recombinant thrombin compared
with R93A,R97A,R101A-thrombin, a recombinant thrombin
mutant with defective heparin binding and heparin-mediated
ternary complex formation with AT (31). Overall, the rate
constants of inhibition by wt-rHCII were not substantially
different when comparing a-thrombin, R93A,R97A,R101A-
thrombin, and wild type recombinant thrombin (Table I). For
L444R-rHCII, all the inhibition rates were slightly higher with
R93A,R97A,R101A-thrombin as compared with a-thrombin
and wild type recombinant thrombin. However, dermatan sul-
fate-accelerated inhibition of wild type recombinant thrombin
was slightly higher but not significantly different than that of
R93A,R97A,R101A-thrombin.
Stoichiometry of Inhibition in the Absence and the Presence of
Glycosaminoglycans—The SI, the number of serpin molecules
consumed before an inactivated serpin-proteinase complex
forms, reflects the tendency of a serpin to behave as a sub-
strate. The titration curves for L444R-rHCII and wt-rHCII
with a-thrombin and R93A,R97A,R101A-thrombin are shown
in Fig. 1. In the absence of glycosaminoglycan, approximately
seven molecules of L444R-rHCII are required to inhibit
a-thrombin before a stable complex is formed. Dermatan sul-
fate decreased the SI value to 2.5, whereas heparin increased it
to 14.5, suggesting that heparin promoted a more substrate-
like behavior for L444R-rHCII. With R93A,R97A,R101A-
thrombin, the SI values in the absence of glycosaminoglycan
(SI 5 7.5) and in the presence of dermatan sulfate (SI 5 2.5)
were comparable with those obtained with a-thrombin. In
contrast, the addition of heparin (SI 5 3) to the R93A,
R97A,R101A-thrombin inhibition reaction had the opposite ef-
fect it did with a-thrombin and mimicked the results obtained
with dermatan sulfate. Wild type rHCII had an SI value rang-
ing from 1.8 to 3 in either the presence of heparin or dermatan
sulfate with either thrombin variant. SI assays were also per-
formed with wild type recombinant thrombin, and the data
agree with those obtained for a-thrombin (data not shown).
Immunoblot Analysis of Thrombin-HCII Reactions—The
substrate activity of wt-rHCII and L444R-rHCII in the absence
and the presence of glycosaminoglycan was visualized by SDS-
PAGE and immunoblot analysis (Fig. 2). Incubation of wt-
rHCII with a-thrombin or R93A,R97A,R101A-thrombin in the
presence of heparin or dermatan sulfate resulted in a stable
bimolecular complex with no apparent proteolysis of the inhib-
itor (Fig. 2). Although heparin and dermatan sulfate acceler-
ated complex formation between wt-rHCII and either thrombin
variant, they had no effect on substrate activity. In the absence
of glycosaminoglycan, neither complex formation nor proteoly-
sis of wt-rHCII was visualized. In contrast, L444R-rHCII had
moderate substrate activity with a-thrombin in the absence of
glycosaminoglycan. After 30 min of incubation, approximately
10–25% of L444R-rHCII is converted to a lower molecular
weight form, consistent with proteolysis at the reactive site
loop. Heparin accelerated the conversion of L444R-rHCII to a
lower molecular weight form, with approximately 90% of the
L444R-rHCII being cleaved by a-thrombin after 30 min of incu-
bation. Interestingly, dermatan sulfate prevented L444R-rHCII
cleavage by a-thrombin. Incubation of R93A,R97A,R101A-throm-
bin with L444R-rHCII in the absence or the presence of derma-
tan sulfate yielded results identical to those observed with
a-thrombin. However, heparin failed to facilitate the proteolytic
TABLE I
Rate constants of inhibition
Inhibition rate constants (k2, M
21 min21) for wt-rHCII and L444R-
rHCII with a-thrombin, R93A, R97A, R101A-thrombin, and wild type
recombinant thrombin are summarized below. For glycosaminoglycan-
accelerated inhibition, template curves were performed in the presence
of increasing concentrations of glycosaminoglycan, and the maximal
inhibition rate from each individual curve was used in the calculation of
the average inhibition rate. Assays were performed as described under
“Experimental Procedures,” and the values are expressed as the









2 GAGa 2.4 6 0.3 3 104b 2.5 6 0.7 3 104e 2.7 6 0.9 3 104c
1 heparin 5.6 6 1.5 3 108c 2.7 6 0.4 3 108b 5.9 6 2.1 3 108c
1 DS 1.2 6 0.2 3 109c 1.1 6 0.1 3 109b 1.1 6 0.07 3 109c
L444R-rHCII
2 GAG 1.3 6 0.3 3 106c 2.6 6 0.3 3 106b 2.3 6 1.4 3 106f
1 heparin 1.1 6 0.5 3 108d 2.7 6 0.2 3 108b 1.7 6 1.1 3 108b
1 DS 2.5 6 0.1 3 108b 4.3 6 0.5 3 108b 6.4 6 1.9 3 108c
a GAG, glycosaminoglycan; DS, dermatan sulfate.
b n 5 4.
c n 5 3.
d n 5 6.
e n 5 5.
f n 5 2.
FIG. 1. Stoichiometry of HCII-thrombin inhibition. Stoichiome-
try of inhibition assays were performed as detailed under “Experimen-
tal Procedures” with a-thrombin (left panels) or R93A,R97A,R101A-
thrombin (right panels) in the presence of increasing concentrations of
wt-rHCII (top panels) or L444R-rHCII (bottom panels). The curves
shown are the averages from two or three recombinant protein prepa-
rations each assayed one to three times. The percentage of remaining
thrombin activity, plotted on the y axis, was determined for each serpin/
proteinase ratio, plotted on the x axis, in the absence of glycosamin-
oglycan (M) and in the presence of heparin (l) or dermatan sulfate (L).
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inactivation of L444R-rHCII by R93A,R97A,R101A-thrombin as
it did with a-thrombin. Longer exposures of the autoradiograph
revealed SDS-PAGE-stable complexes between L444R-rHCII
and thrombin for all combinations except L444R-rHCII/a-throm-
bin/heparin (data not shown).3
Extended Time Course of HCII-Thrombin Reactions—The
HCII and thrombin variants were incubated for various time
periods up to 18 h in order to determine the time course and
stability of thrombin inhibition. Shown in Fig. 3 is a represent-
ative plot of thrombin inhibition by L444R-rHCII in the ab-
sence and the presence of glycosaminoglycan. Inhibition of
R93A,R97A,R101A-thrombin by L444R-rHCII occurs rapidly
and is sustained over a 18-h period. Likewise, the inhibition of
a-thrombin by L444R-rHCII in the absence of glycosaminogly-
can and in the presence of dermatan sulfate is also sustained
during the course of the experiment. In the presence of heparin,
a-thrombin is rapidly inhibited during the first 30–60 min, but
activity is slowly regained thereafter. Within 6 h of incubation,
approximately 75–80% of a-thrombin activity is regained and
is stable for at least 18 h. The instability of a-thrombin inhibi-
tion is due to the dissociation of L444R-rHCII/a-thrombin com-
plexes promoted by heparin. There was no remaining thrombin
activity at the 18-h time point for wt-rHCII with either throm-
bin derivative in the presence of heparin (data not included).
Role of Heparin and Heparin Fragments on the Substrate
Activity of L444R-rHCII—To determine whether heparin
bridging of a-thrombin to L444R-rHCII was a factor in the
substrate-like behavior of L444R-rHCII, thrombin inhibition
assays with heparin fragments of 8–20 polysaccharides in
length (HF8, HF12, HF16, and HF20) were performed. The
minimal heparin length required for ternary complex forma-
tion is thought to be between 18 and 26 polysaccharides (16,
33–35).4 Thus, we postulated that the heparin-mediated inac-
tivation of L444R-rHCII by a-thrombin would decrease with
decreasing heparin fragment length. We chose an 18-h incuba-
tion time to insure that the reaction process reached comple-
tion with regards to either proteinase inhibition or serpin in-
activation with release of thrombin. Both a-thrombin and
R93A,R97A,R101A-thrombin were essentially completely in-
hibited after 18 h of incubation in the presence of wt-rHCII and
HF12, HF16, HF20, or heparin; approximately 5–10% of ac-
tivity remained with the HF8, consistent with the lower inhi-
bition rate of wt-rHCII with a short heparin fragment (Fig. 4).
The same results were obtained for L444R-rHCII with
R93A,R97A,R101A-thrombin. In contrast, approximately 30
and 46% of a-thrombin activity remained when incubated with
L444R-rHCII and HF16 or HF20, respectively, as compared
with approximately 5% remaining activity with HF8 or HF12.
Control experiments verified that all of the heparin fragments
accelerated thrombin inhibition by L444R-rHCII as found pre-
viously with other heparin-binding serpins (16). However, un-
like HF8 and HF12, which supported complete a-thrombin
inhibition by L444R-rHCII, HF16- and HF20-accelerated
a-thrombin inhibition leveled off after 30 min of incubation,
which would be consistent with inactivation of L444R-rHCII
(data not included).
3 The rapid heparin-accelerated inhibition of a-thrombin by L444R-
rHCII would lead one to predict the formation of SDS-PAGE-stable
complexes. However, there are multiple examples in the literature of
serpin-proteinase pairs that form highly stable complexes under native
but not under denaturing conditions. Under different experimental
conditions where higher concentration of L444R-rHCII and a-thrombin
were used, SDS-PAGE-stable complexes were visualized in the pres-
ence of heparin.
4 Heparin-accelerated thrombin inhibition by HCII decreases linearly
with decreasing heparin size (16, 35), but because ternary complex
formation is not required for the inhibition reaction, the minimal hep-
arin length required for bridging is difficult to estimate from these
studies. Because ternary complex formation between AT/thrombin/hep-
arin is required for the inhibition reaction, it is possible to deduce a
minimal size requirement for heparin bridging AT to thrombin. Based
upon the sequence homology between AT and HCII, upon localization of
their heparin binding sites to the D helix region, and from our compar-
ison of molecular models of HCII-thrombin and AT-thrombin complexes
in the presence of heparin, we would predict that AT-thrombin and
HCII-thrombin complexes require heparin molecules of a similar length
to successfully bridge the serpin and thrombin together.
FIG. 2. Immunoblot analysis of HCII-thrombin reactions. Im-
munoblots of HCII-thrombin reactions between L444R-rHCII (A and B)
or wt-rHCII (C and D) and a-thrombin (A and C) or R93A,R97A,R101A-
thrombin (B and D) were prepared as detailed under “Experimental
Procedures.” The reactions were performed in the absence of glycosami-
noglycan (2GAG) or in the presence of heparin (1hep) or dermatan
sulfate (1ds) for 1, 5, or 30 min as indicated above the immunoblots. For
C and D, only the 30-min time point is shown. Lanes labeled with a 0
contain HCII alone.
FIG. 3. Extended time course of HCII-thrombin reactions.
L444R-rHCII and thrombin were incubated together for various times
up to 18 h, and the residual thrombin activity at each time point was
determined as detailed under “Experimental Procedures.” A represent-
ative experiment depicting a time course of a-thrombin (A) or
R93A,R97A,R101A-thrombin (B) inhibition by L444R-rHCII in the ab-
sence of glycosaminoglycan (M) or in the presence of heparin (l) or
dermatan sulfate (L) is shown.
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DISCUSSION
Mutations in the reactive site loop of numerous serpins have
altered their proteinase specificity and inhibitory activity (Refs.
19–22, 36, 37; for a review see Ref. 38). The regions studied most
intensively have been the P1-P19 residues and the residues of the
hinge region (P9-P15), where the reactive site loop turns and
joins the A b-sheet as strand 5A. A common prediction from these
studies would be that increased inhibitory activity (measured by
k2 values) would give lower SI values. Furthermore, increased
substrate activity would be correlated with reduced inhibitory
activity. In 1990, Derechin et al. (25) prepared an HCII mutant
with a P1 residue substitution of Leu to Arg with the expectation
that this form of rHCII would be a superb thrombin inhibitor
(measured by k2 values). In the absence of glycosaminoglycans,
their mutant was about 100-fold more active than wild type
recombinant HCII. However, the maximal rate enhancement of
thrombin inhibition by glycosaminoglycans was lower with
L444R-rHCII than with wt-rHCII.5 We became interested in
further exploring the mechanism of action of this “ideal” throm-
bin inhibitor in the absence and the presence of glycosaminogly-
cans. The present study shows that substitution of an Arg at the
P1 Leu position of rHCII increases its thrombin inhibitory activ-
ity in the absence of glycosaminoglycan but also increases its
substrate activity. Although heparin and dermatan sulfate both
accelerate a-thrombin inhibition by L444R-rHCII to levels
slightly lower than with wt-rHCII, heparin, but not dermatan
sulfate, promotes the proteolytic inactivation of L444R-rHCII by
a-thrombin.
Heparin-induced proteolytic inactivation of a related serpin,
AT, was described previously by Olson (23). AT was shown to
be an inhibitor in the presence of heparin at physiological ionic
strength, but at lower ionic strength, heparin promoted the
substrate pathway of AT with thrombin (23). Low ionic
strength presumably increased heparin binding to an anti-
thrombin-thrombin intermediate complex, which normally ex-
hibits low heparin affinity (39–42). Furthermore, only heparin
molecules long enough to bridge thrombin and AT promoted
the substrate pathway. This study showed that the formation
of cleaved AT occurred through a substrate pathway different
than that of the slow spontaneous dissociation of stable anti-
thrombin-thrombin complexes (43). Our results suggest that
unlike AT, heparin affects both the proteolytic inactivation of
excess L444R-rHCII by thrombin and accelerates the slow dis-
sociation of L444R-rHCII-thrombin complexes at physiological
ionic strength. The result of extended time course incubations
of L444R-rHCII with a-thrombin in the presence of heparin
reflects the slow release of active thrombin from ternary com-
plexes composed of L444R-rHCII, thrombin, and heparin. One
plausible explanation is that the heparin-promoted ternary
complex places L444R-rHCII in a favorable position for cleav-
age by a-thrombin; thus, initially, inactivation of L444R-rHCII
and inhibition of thrombin are occurring simultaneously and
over time, the remaining L444R-rHCII that is complexed with
thrombin is slowly cleaved, releasing active thrombin.
AT requires ternary complex formation not only for heparin-
accelerated thrombin inhibition but also for heparin-acceler-
ated inactivation by thrombin (10, 23, 33). With L444R-rHCII,
ternary complex formation mediated by heparin appears nec-
essary only for the proteolytic inactivation by a-thrombin. With
R93A,R97A,R101A-thrombin, which is defective in glycosami-
noglycan binding and ternary complex formation, heparin ac-
celerates its inhibition by L444R-rHCII but not L444R-rHCII
inactivation. Dermatan sulfate, which cannot mediate ternary
complex formation (18), does not promote inactivation of
L444R-rHCII, regardless of which proteinase is used. The re-
quirement of ternary complex formation for L444R-rHCII in-
activation is further supported by the data with small heparin
oligosaccharides of 8 or 12 units. These heparin fragments are
unable to bridge both HCII and thrombin, and they accelerate
a-thrombin inhibition by L444R-rHCII (and wt-rHCII) without
promoting L444R-rHCII inactivation. L444R-rHCII inactiva-
tion by a-thrombin is promoted by heparin oligosaccharides $
16 units, close to the putative minimal length capable of bridg-
ing HCII to thrombin (34, 35).4 The detrimental inactivating
action of the longer heparin oligosaccharides on L444R-rHCII
was absent with R93A,R97A,R101A-thrombin. Thus, ternary
complex formation between heparin, thrombin, and L444R-
rHCII, rather than heparin binding to L444R-rHCII per se,
appears to cause the substrate-like activity of L444R-rHCII.
The differences observed between this study and Olson’s
study (23) are not surprising because HCII and AT appear to
follow different mechanisms of heparin-accelerated thrombin
inhibition. Ternary complex formation is absolutely required
for the heparin-accelerated inhibition of thrombin by AT (10).
Binding of heparin to AT also results in a conformational
change in the reactive site loop that slightly increases the rate
of thrombin inhibition (44–46). Glycosaminoglycan-acceler-
ated thrombin inhibition by HCII occurs through an allosteric
mechanism, whereby binding of the glycosaminoglycan to HCII
facilitates the interaction of a hirudin-like amino-terminal do-
5 The original description comparing L444R-rHCII with wt-rHCII
had a heparin-accelerated a-thrombin inhibition rate for wt-rHCII that
was ;100-fold lower than expected, making this comparison difficult to
interpret (25). A point mutation (H159R) was subsequently found from
a polymerase chain reaction artifact in the HCII cDNA used in the
original study which affected heparin-accelerated but not dermatan
sulfate-accelerated thrombin inhibition by rHCII (51).
FIG. 4. The effect of heparin fragments on the substrate activ-
ity of L444R-rHCII.Heparin fragments of 8–20 polysaccharides (HF8,
HF12, HF16, and HF20) or heparin were added to wt-rHCII (top panel)
or L444R-rHCII (bottom panel) in the presence of either a-thrombin or
R93A,R97A,R101A-thrombin and incubated for 18 h. The results ob-
tained with wild type recombinant thrombin and L444R-rHCII were
identical to those with a-thrombin (data not shown). Assays were per-
formed two or three times for each condition studied, and the figure
shown represents the mean values (6 S.D.). The percentage of remain-
ing thrombin activity on the y axis is plotted for each thrombin and
glycosaminoglycan combination on the x axis.
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main of HCII with anion-binding exosite 1 of thrombin (18).
Ternary complex formation occurs in the presence of heparin
but makes only a minor contribution in HCII inhibition of
thrombin. Dermatan sulfate, which binds thrombin only
weakly and thus does not participate in ternary complex for-
mation, is as effective as heparin in accelerating thrombin
inhibition (15, 47). Thus, the ability of a glycosaminoglycan to
form a ternary complex contributes only minimally to HCII
inhibition of thrombin, implying that heparin and dermatan
sulfate employ similar mechanisms of catalysis of the inhibi-
tion reaction. However, our results suggest different effects of
the two glycosaminoglycans in terms of binding to and inacti-
vation of L444R-rHCII by thrombin. It is possible that ternary
complex formation, mediated by heparin, induces a conforma-
tional change in the reactive site loop that is more readily
detected in L444R-rHCII as an increase in susceptibility to
proteolytic inactivation.
The presence of Leu in the P1 site of HCII has always
presented a dilemma, because thrombin strongly favors cleav-
age after Arg residues. In a previous molecular modeling study,
we found no major binding constraints with the binding pocket
of thrombin for macromolecular substrates containing Pro-Arg
versus Pro-Leu at the P2-P1 positions (32), indicating that
either P1 residue could be accommodated. The recognition sites
of different macromolecular substrates and inhibitors of throm-
bin were compared, and it was found that the P1 residue was
almost exclusively Arg, whereas Pro was preferred at the P2
residue (48, 49). Thus, the L444R-rHCII reactive site sequence
would be an ideal thrombin recognition sequence because it has
a P2-P1-P19 sequence of Pro-Arg-Ser. HCII may have evolved
with a P1 Leu residue in order to remain essentially inactive in
the absence of glycosaminoglycans (i.e. while circulating in
blood). In its glycosaminoglycan-bound active form, HCII com-
pensates for its lack of an ideal P1 residue by the presence of its
hirudin-like acidic domain, which interacts with anion-binding
exosite 1 of thrombin. HCII-thrombin inhibitory activity is
believed to be localized to proteoglycan-rich surfaces. Because
HCII and thrombin both bind glycosaminoglycans, their co-
localization to these sites might result in ternary complex for-
mation concomitant with the inhibition reaction. Therefore, the
P1 Leu would render HCII relatively resistant to inactivation
by thrombin in the presence of proteoglycans that might in fact
mediate ternary complex formation.
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